
Four of eight evaluable patients had confirmed partial responses, all ongoing at the September data cutoff, the company said.
Iovance Biotherapeutics said one-time lifileucel treatment produced a 50% confirmed response rate among the first eight evaluable patients in a pilot study of advanced soft tissue sarcomas.
The four partial responses, two in undifferentiated pleomorphic sarcoma and two in dedifferentiated liposarcoma, were all ongoing as of September 9. They had lasted at least 6, 26, 40 and 46 weeks, respectively. The company said the treatment’s safety profile was consistent with its use in other indications.
Iovance said its registrational Phase 2 SARATOGA trial is enrolling patients with the two cancers at Memorial Sloan Kettering Cancer Center and other major U.S. cancer centers.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.